NTRK3

(redirected from TrkC)
Also found in: Acronyms, Wikipedia.

NTRK3

A gene on chromosome 15q25 that encodes TrkC receptor, a tyrosine-protein kinase receptor activated by neurotrophin-3 (NT-3) and is found on proprioceptive sensory neurons; its substrates include SHC1, PI-3 kinase and PLCG1.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
trkC exists either as a full-length (140 kDa) protein or as a truncated (90-95 kDa) protein.
Both TrkA and TrkC receptors express immunoreactivity in the bovine follicular cells (Munoz et al., 2009), and NGF and TrkA proteins are expressed in granulosa cells, where NGF and its receptors play an essential role in the ovulation process (Dissen et al., 2000).
In the study, NT-3 was found to be expressed at increased levels in aggressive human neuroblastomas and to block the ability of TrkC to induce tumour cell death by a process known as apoptosis.
Thus the trkA-expressing PC12 cells and chromaffin cells are in good contrast with central neurons expressing trkB or trkC corresponding to BDNF or NT-3 (see |9, 10~ for reviews).
The acquired solvent front mutations including ALK G1202R, ROS1 G2032R, TRKA G595R and TRKC G623R render a common clinical resistance to the current ALK, ROS1, and TRK inhibitors.
Lu et al., "Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas," Cancer Research, vol.
Teng, "Cograft of neural stem cells and Schwann cells overexpressing TrkC and neurotrophin-3 respectively after rat spinal cord transection," Biomaterials, vol.
Tropomyosin receptor kinases (TRKA through TRKC) bind the neurotrophin family of ligands, including nerve growth factor, and have been implicated in tumorigenesis.
verified that transplantation of MSCs expressing MNTS1, a multineurotrophin that binds TrkA, TrkB, and TrkC and p75NTR receptors, led to recovery of sensory function, promoting axonal growth after SCI [45].
The product is a new orally available, selective tyrosine kinase inhibitor and is designed as a targeted therapeutic candidate to treat patients with cancers that harbour activating alterations to TrkA, TrkB, TrkC, ROS1 or ALK.
NTRK fusion gene is an abnormal gene that can be formed by fusing the NTRK genes (NTRK1, NTRK2, NTRK3encode TRKA, TRKB, TRKC protein, respectively) and other genes (ETV6, LMNA, TPM3, etc.) as a result of chromosomal translocation1-3).